3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today

Motley Fool2022-02-21

The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

411

Report

Comment（28）

adonis123
·2022-02-22
Better to keep your bullets in these uncertain times
Reply
1
Report
adonis123
·2022-02-22
Better to keep your bullets in these uncertain times.
Reply
1
Report
adonis123
·2022-02-22
Better to keep your bullets in these uncertain times
Reply
Like
Report
Jess261
·2022-02-22
okay
Reply
1
Report
SCLIEW
·2022-02-22
666
Reply
Like
Report
WaiSiong81
·2022-02-22
👍
Reply
1
Report
daz888888888
·2022-02-22
Volatile because of Madame Putin
Reply
1
Report
Gladys8jk
·2022-02-22
Ok
Reply
1
Report
BettyT
·2022-02-22
Have to observe the market movements before adding bullets into it. Furthermore, the market is not stable nowadays.
Reply
3
Report
BKT
·2022-02-21
Good. Pls like thanks.
Reply
2
Report
Wilfredlauu
·2022-02-21
Ok
Reply
1
Report
Chris68
·2022-02-21
👌
Reply
4
Report
AlphaSpiker
·2022-02-21
Buy later will be cheaper, even Warren Buffet can't be right all the time, but during his time he was right 😁
Reply
3
Report
Ignis
·2022-02-21
Hahaha
Reply
3
Report
蒋小鱼
·2022-02-21
Better think twice before buying. Later drop even lower
Reply
7
Report
TBKeith
·2022-02-21
Nice
Reply
2
Report
SK19
·2022-02-21
💪💪💪
Reply
1
Report
Alvin1975
·2022-02-21
Up
Reply
2
Report
masran
·2022-02-21
good
Reply
2
Report
ZenInv
·2022-02-21
What can we do without Amazon?
Reply
3
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2212967058?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-21 17:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2212967058","market":"us","top_or_hot":-1,"title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","media":"Motley Fool","content":"<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMZN","symbol_name":"亚马逊","start_time":0,"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","article_id":"2212967058","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","pubTimestamp":1645434134,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"The market has been choppy lately, but these stocks look like great buys.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMZN":"亚马逊","CRWD":"CrowdStrike Holdings, Inc.","VRTX":"福泰制药"},"translate_title":"3个不可阻挡的纳斯达克领跑者你今天仍然可以买到","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMZN":0.9,"CRWD":0.9,"VRTX":0.9},"content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9097599933,"gmtCreate":1645492360927,"gmtModify":1676534032800,"author":{"id":"4087116753605820","authorId":"4087116753605820","name":"adonis123","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":3,"crmLevelSwitch":0,"idStr":"4087116753605820","authorIdStr":"4087116753605820"},"htmlText":"Better to keep your bullets in these uncertain times","listText":"Better to keep your bullets in these uncertain times","text":"Better to keep your bullets in these uncertain times","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097599933","repostId":2212967058,"repostType":4,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097590261,"gmtCreate":1645492315499,"gmtModify":1676534032825,"author":{"id":"4087116753605820","authorId":"4087116753605820","name":"adonis123","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":3,"crmLevelSwitch":0,"idStr":"4087116753605820","authorIdStr":"4087116753605820"},"htmlText":"Better to keep your bullets in these uncertain times.","listText":"Better to keep your bullets in these uncertain times.","text":"Better to keep your bullets in these uncertain times.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097590261","repostId":2212967058,"repostType":4,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097590027,"gmtCreate":1645492272593,"gmtModify":1676534032782,"author":{"id":"4087116753605820","authorId":"4087116753605820","name":"adonis123","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":3,"crmLevelSwitch":0,"idStr":"4087116753605820","authorIdStr":"4087116753605820"},"htmlText":"Better to keep your bullets in these uncertain times","listText":"Better to keep your bullets in these uncertain times","text":"Better to keep your bullets in these uncertain times","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097590027","repostId":2212967058,"repostType":4,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097503931,"gmtCreate":1645491039450,"gmtModify":1676534032400,"author":{"id":"3586490638953193","authorId":"3586490638953193","name":"Jess261","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3586490638953193","authorIdStr":"3586490638953193"},"htmlText":"okay","listText":"okay","text":"okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097503931","repostId":2212967058,"repostType":4,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097276580,"gmtCreate":1645490261282,"gmtModify":1676534032265,"author":{"id":"4092970777728640","authorId":"4092970777728640","name":"SCLIEW","avatar":"https://static.tigerbbs.com/5da553e4d3d35db75d1caae023ca8a03","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4092970777728640","authorIdStr":"4092970777728640"},"htmlText":"666","listText":"666","text":"666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097276580","repostId":2212967058,"repostType":4,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097247247,"gmtCreate":1645489575596,"gmtModify":1676534032132,"author":{"id":"4092698747642690","authorId":"4092698747642690","name":"WaiSiong81","avatar":"https://static.tigerbbs.com/81c10c8d3ad2387a719eaa62a541371f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4092698747642690","authorIdStr":"4092698747642690"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097247247","repostId":2212967058,"repostType":4,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097251661,"gmtCreate":1645488110360,"gmtModify":1676534031652,"author":{"id":"4088639346266630","authorId":"4088639346266630","name":"daz888888888","avatar":"https://community-static.tradeup.com/news/8bbe8cd95504dc1e0dd3af78504d3f7e","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":4,"crmLevelSwitch":0,"idStr":"4088639346266630","authorIdStr":"4088639346266630"},"htmlText":"Volatile because of Madame Putin","listText":"Volatile because of Madame Putin","text":"Volatile because of Madame Putin","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097251661","repostId":2212967058,"repostType":4,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097263548,"gmtCreate":1645486132802,"gmtModify":1676534031123,"author":{"id":"4094787128284850","authorId":"4094787128284850","name":"Gladys8jk","avatar":"https://static.tigerbbs.com/789bbf473867763cd44be080e269826d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4094787128284850","authorIdStr":"4094787128284850"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097263548","repostId":2212967058,"repostType":4,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097205567,"gmtCreate":1645459905400,"gmtModify":1676534029846,"author":{"id":"3580536610076415","authorId":"3580536610076415","name":"BettyT","avatar":"https://static.tigerbbs.com/6a4dfe2f455acd2af7629f83ce30e20c","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3580536610076415","authorIdStr":"3580536610076415"},"htmlText":"Have to observe the market movements before adding bullets into it. Furthermore, the market is not stable nowadays.","listText":"Have to observe the market movements before adding bullets into it. Furthermore, the market is not stable nowadays.","text":"Have to observe the market movements before adding bullets into it. Furthermore, the market is not stable nowadays.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097205567","repostId":2212967058,"repostType":4,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097200270,"gmtCreate":1645458035479,"gmtModify":1676534029613,"author":{"id":"3570853427202414","authorId":"3570853427202414","name":"BKT","avatar":"https://community-static.tradeup.com/news/15cb8e8f0a7c44ca01c83b3bfdddbd86","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3570853427202414","authorIdStr":"3570853427202414"},"htmlText":"Good. Pls like thanks.","listText":"Good. Pls like thanks.","text":"Good. Pls like thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097200270","repostId":2212967058,"repostType":4,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097646725,"gmtCreate":1645454266722,"gmtModify":1676534029331,"author":{"id":"3569124005600576","authorId":"3569124005600576","name":"Wilfredlauu","avatar":"https://static.tigerbbs.com/237fc4cbfdfe4189c450c466597328a4","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"idStr":"3569124005600576","authorIdStr":"3569124005600576"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097646725","repostId":2212967058,"repostType":4,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097641253,"gmtCreate":1645453559915,"gmtModify":1676534029240,"author":{"id":"3575974639321365","authorId":"3575974639321365","name":"Chris68","avatar":"https://static.tigerbbs.com/1ae39a12c3ba237f3b001689ec9a549b","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3575974639321365","authorIdStr":"3575974639321365"},"htmlText":"👌&nbsp;","listText":"👌&nbsp;","text":"👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097641253","repostId":2212967058,"repostType":4,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097651269,"gmtCreate":1645451330014,"gmtModify":1676534028960,"author":{"id":"3573008930783156","authorId":"3573008930783156","name":"AlphaSpiker","avatar":"https://static.tigerbbs.com/7bf4e96af844a7e9da5720d6045b3532","vip":1,"crmLevel":6,"crmLevelSwitch":1,"idStr":"3573008930783156","authorIdStr":"3573008930783156"},"htmlText":"Buy later will be cheaper, even Warren Buffet can't be right all the time, but during his time he was right 😁","listText":"Buy later will be cheaper, even Warren Buffet can't be right all the time, but during his time he was right 😁","text":"Buy later will be cheaper, even Warren Buffet can't be right all the time, but during his time he was right 😁","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097651269","repostId":2212967058,"repostType":4,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097651349,"gmtCreate":1645451243751,"gmtModify":1676534028960,"author":{"id":"3574686466924712","authorId":"3574686466924712","name":"Ignis","avatar":"https://static.tigerbbs.com/543d1f3e8b4901fba226eb61e5713bc4","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":4,"crmLevelSwitch":0,"idStr":"3574686466924712","authorIdStr":"3574686466924712"},"htmlText":"Hahaha","listText":"Hahaha","text":"Hahaha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097651349","repostId":2212967058,"repostType":4,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097625361,"gmtCreate":1645449455914,"gmtModify":1676534028815,"author":{"id":"4094549885200800","authorId":"4094549885200800","name":"蒋小鱼","avatar":"https://static.tigerbbs.com/e246cd92d12ee8510cba3c63485f6922","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"4094549885200800","authorIdStr":"4094549885200800"},"htmlText":"Better think twice before buying. Later drop even lower","listText":"Better think twice before buying. Later drop even lower","text":"Better think twice before buying. Later drop even lower","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097625361","repostId":2212967058,"repostType":4,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097628094,"gmtCreate":1645448449741,"gmtModify":1676534028737,"author":{"id":"3582018639606874","authorId":"3582018639606874","name":"TBKeith","avatar":"https://static.tigerbbs.com/3153e5158711508229717de5319441c3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582018639606874","authorIdStr":"3582018639606874"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097628094","repostId":2212967058,"repostType":2,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097621796,"gmtCreate":1645448444243,"gmtModify":1676534028730,"author":{"id":"3577755293052640","authorId":"3577755293052640","name":"SK19","avatar":"https://static.tigerbbs.com/ee6b25332525b16399562f21677fa1cd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577755293052640","authorIdStr":"3577755293052640"},"htmlText":"💪💪💪","listText":"💪💪💪","text":"💪💪💪","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097621796","repostId":2212967058,"repostType":4,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097689623,"gmtCreate":1645441151766,"gmtModify":1676534027904,"author":{"id":"3573788625955643","authorId":"3573788625955643","name":"Alvin1975","avatar":"https://static.tigerbbs.com/beba0668af2d109b87221754e75935b3","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3573788625955643","authorIdStr":"3573788625955643"},"htmlText":"Up","listText":"Up","text":"Up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097689623","repostId":2212967058,"repostType":4,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097689333,"gmtCreate":1645441107064,"gmtModify":1676534027896,"author":{"id":"3582888796077977","authorId":"3582888796077977","name":"masran","avatar":"https://static.tigerbbs.com/5258de17f60ac17503ecfa2ededa974d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582888796077977","authorIdStr":"3582888796077977"},"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097689333","repostId":2212967058,"repostType":4,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9097612592,"gmtCreate":1645440234448,"gmtModify":1676534027821,"author":{"id":"4098783902581330","authorId":"4098783902581330","name":"ZenInv","avatar":"https://community-static.tradeup.com/news/033bd47e3df1977aaef462f53997e9f1","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4098783902581330","authorIdStr":"4098783902581330"},"htmlText":"What can we do without Amazon?","listText":"What can we do without Amazon?","text":"What can we do without Amazon?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9097612592","repostId":2212967058,"repostType":4,"repost":{"id":"2212967058","kind":"highlight","pubTimestamp":1645434134,"share":"https://ttm.financial/m/news/2212967058?lang=&edition=fundamental","pubTime":"2022-02-21 17:02","market":"us","language":"en","title":"3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2212967058","media":"Motley Fool","summary":"The market has been choppy lately, but these stocks look like great buys.","content":"<html><head></head><body><p>The <b>Nasdaq Composite</b> index is now down 13.4% across 2022&#39;s trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn&#39;t fret too much over recent volatility.</p><p>Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here&#39;s why a panel of Motley Fool contributors identified <a href=\"https://laohu8.com/S/AMZN\">Amazon </a>, <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a>, and <a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a> as unstoppable businesses that are primed to deliver big wins for shareholders.</p><h2>Amazon is finally a good value</h2><p><b>Daniel Foelber </b><a href=\"https://laohu8.com/S/AMZN\">Amazon </a><b>:</b> One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it&#39;s worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.</p><p>When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.</p><p>Gone are the days of Amazon&#39;s lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.</p><p>Arguably the most impressive aspect of Amazon&#39;s business is Amazon Web Services (AWS), which is the company&#39;s cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.</p><p>But here&#39;s the real kicker -- AWS made up just 13% of Amazon&#39;s 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon&#39;s other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.</p><p>Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today&#39;s rising-interest-rate environment, it wouldn&#39;t surprise me if Amazon beat the Nasdaq in 2022 and beyond.</p><h2>There&#39;s pharma opportunity beyond COVID-19</h2><p><b>James Brumley</b> <a href=\"https://laohu8.com/S/VRTX\">Vertex Pharmaceuticals </a><b>:</b> Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That&#39;s where the bulk of the biggest and best near-term opportunity was.</p><p>The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020&#39;s peak near $300 to this past October&#39;s low of around $180.</p><p>The market seems to have caught on to its mistake. Vertex&#39;s shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta&#39;s revenue, in fact, improved more than 50% year over year during the final quarter of last year.</p><p>Arguably, though, the stock is still not fully reflecting the company&#39;s full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year&#39;s $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock&#39;s only trading at 15.3 times 2023&#39;s projected profits. You don&#39;t see too many stocks growing actual profits this quickly at that sort of valuation.</p><h2>Tap into surging demand for cybersecurity services</h2><p><b>Keith Noonan </b><a href=\"https://laohu8.com/S/CRWD\">CrowdStrike Holdings </a><b>:</b> Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world&#39;s leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.</p><p>If you&#39;re looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company&#39;s share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there&#39;s a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader&#39;s services is incredibly strong, and the growth story here is just getting started.</p><p>Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike&#39;s software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.</p><p>As more customers join the company&#39;s platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it&#39;s poised to continue being a category leader over the long term.</p><p>With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Nasdaq Front-Runners You Can Still Buy Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-21 17:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊","VRTX":"福泰制药","CRWD":"CrowdStrike Holdings, Inc."},"source_url":"https://www.fool.com/investing/2022/02/20/3-unstoppable-nasdaq-front-runners-you-can-still-b/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2212967058","content_text":"The Nasdaq Composite index is now down 13.4% across 2022's trading and 16.4% from the high that it hit last year. Many growth-dependent stocks in the index have seen even more dramatic pullbacks from their highs, but investors shouldn't fret too much over recent volatility.Backing great companies over the long term remains a top avenue for generating wealth, and recent market turbulence has given investors chances to buy great stocks at cheaper prices. With that in mind, here's why a panel of Motley Fool contributors identified Amazon , Vertex Pharmaceuticals , and CrowdStrike Holdings  as unstoppable businesses that are primed to deliver big wins for shareholders.Amazon is finally a good valueDaniel Foelber Amazon : One look at an Amazon stock chart, and you realize how brutal the stock market can be in the short term. Amazon stock is down 8% year to date, which is better than the Nasdaq Composite and many other big tech stocks. But it's worth mentioning that Amazon is down despite posting blowout fourth-quarter 2021 and full-year 2021 results.When the market is bleeding red, valuation, long-term growth, and fundamentals matter more than ever. And Amazon has these qualities in spades.Gone are the days of Amazon's lofty valuation. It raked in a staggering $469.8 billion in 2021 revenue and $33.4 billion in net income, giving it a price-to-sales (P/S) ratio of 3.3 and a price-to-earnings (P/E) ratio of 47 -- which is the lowest P/E ratio Amazon has had since 2009. Amazon continues to reinvest in the business. If it were to reel in its spending, it could easily open the tap and generate even more profit.Arguably the most impressive aspect of Amazon's business is Amazon Web Services (AWS), which is the company's cloud computing segment. AWS brought in $62.2 billion in 2021 sales and $18.5 billion in operating income, giving it an operating margin of 30%.But here's the real kicker -- AWS made up just 13% of Amazon's 2021 revenue but 74% of its operating income. Put another way, AWS is a cash cow that is funding Amazon's other investments. Throw in a steadily growing core retail business, which is low-margin and high-volume, and you have a one-two punch built to outlast a market crash.Out of the seven largest Nasdaq components, Amazon is the only one that underperformed the Nasdaq between 2019 and the end of 2021. Given the emphasis on profit and value in today's rising-interest-rate environment, it wouldn't surprise me if Amazon beat the Nasdaq in 2022 and beyond.There's pharma opportunity beyond COVID-19James Brumley Vertex Pharmaceuticals : Over the course of the past couple of years, investor interest in pharmaceutical stocks has been mostly limited to names working on COVID-19 vaccines and treatments. And that makes sense. That's where the bulk of the biggest and best near-term opportunity was.The problem: That took away too much focus on companies that continued making great strides in their development of drugs to treat other ailments. Vertex Pharmaceuticals is one of these forgotten tickers. Despite its ongoing work to treat cystic fibrosis, muscular dystrophy, diabetes, and other difficult-to-address conditions, the stock fell from 2020's peak near $300 to this past October's low of around $180.The market seems to have caught on to its mistake. Vertex's shares have rallied roughly 30% from that low, mostly thanks to continued sales growth of its cystic fibrosis drug Trikafta, but also due to encouraging results with its midstage trial of VX-147 for the treatment of kidney disease. Trikafta's revenue, in fact, improved more than 50% year over year during the final quarter of last year.Arguably, though, the stock is still not fully reflecting the company's full potential, which was ignored during the throes of the pandemic. If earnings grow as expected from last year's $13.02 per share to $14.21 this year and $15.22 per share next year, then the stock's only trading at 15.3 times 2023's projected profits. You don't see too many stocks growing actual profits this quickly at that sort of valuation.Tap into surging demand for cybersecurity servicesKeith Noonan CrowdStrike Holdings : Cyber attacks are the fastest-growing category of crime in the U.S., and digital breaches pose a huge risk to businesses and institutions. CrowdStrike is the world's leading provider of cloud-based endpoint cybersecurity services, and its software helps minimize network vulnerabilities and protect valuable data.If you're looking for worthwhile long-term investments on the heels of recent tech sector sell-offs, CrowdStrike deserves a spot on your list. The company's share price has slid 19.5% year to date and roughly 43% from its peak, and I believe there's a great chance it will bounce back and go on to reach new highs. The long-term demand outlook for the cybersecurity leader's services is incredibly strong, and the growth story here is just getting started.Vulnerabilities in computer systems, mobile devices, servers, and other hardware can be used by bad actors to gain access to networks, allowing them to steal or alter valuable information and cause massive financial and reputational damage. CrowdStrike's software platform uses artificial intelligence for threat detection, analysis, and response actions, and it learns with each attack it encounters and evolves to provide improved protection.As more customers join the company's platform and more cybersecurity attacks come its way, the software becomes smarter and provides improved value for clients. This gives the company a powerful network effect, and it's poised to continue being a category leader over the long term.With organizations carrying out digital transformation initiatives and more connected devices being added to networks all the time, high-performance endpoint protection will only become increasingly important. CrowdStrike is set to deliver strong growth as it continues to attract new customers and sells added services to those already on board with its platform, and its stock offers huge return potential and an attractive risk-reward dynamic for patient investors.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":411,"commentSize":28,"repostSize":0,"favoriteSize":4,"likeStatus":false,"favoriteStatus":false}}